<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956225</url>
  </required_header>
  <id_info>
    <org_study_id>DEG723-P001</org_study_id>
    <nct_id>NCT03956225</nct_id>
  </id_info>
  <brief_title>Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study</brief_title>
  <official_title>Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-approval study is to demonstrate that iLux treatment offers&#xD;
      comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be expected to attend a total of 8 study visits, including Screening/Baseline,&#xD;
      Treatment, and follow-up visits at Week 2 and Months 1, 3, 6, 9, and 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Actual">October 24, 2020</completion_date>
  <primary_completion_date type="Actual">October 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Squares Mean Change From Baseline in Meibomian Gland Score (MGS) at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Meibomian glands on the eyelids were assessed by the examiner using a Meibomian Gland Evaluator and a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated for each eye and scored from 0 to 3, with a resultant overall score (MGS) of 0 to 45 for each eye. Scoring was follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A higher change from baseline score indicates an improvement in meibomian gland function.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <condition>Evaporative Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>iLux</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes will be treated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LipiFlow</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes will be treated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Systane iLux® Dry Eye System</intervention_name>
    <description>Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.</description>
    <arm_group_label>iLux</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipiFlow® Thermal Pulsation System</intervention_name>
    <description>Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.</description>
    <arm_group_label>LipiFlow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and sign an Informed Consent document;&#xD;
&#xD;
          -  Have Meibomian Gland Dysfunction with evaporative dry eye disease at the screening&#xD;
             visit;&#xD;
&#xD;
          -  Agree not to wear contact lenses for the duration of the study;&#xD;
&#xD;
          -  Other protocol-specified inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of eye surgery, as specified in the protocol;&#xD;
&#xD;
          -  Eye infection or inflammation, as specified in the protocol;&#xD;
&#xD;
          -  Eyelid abnormalities; eyelid tattoos;&#xD;
&#xD;
          -  Treated with LipiFlow or iLux in either eye in the last 12 months;&#xD;
&#xD;
          -  Contact lens wear within the 1 month prior to Screening;&#xD;
&#xD;
          -  Other protocol-specified exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Lead, Vision Care</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigator 9083</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 9081</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 9084</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 5127</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 4782</name>
      <address>
        <city>Highland Park</city>
        <state>Illinois</state>
        <zip>60035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6567</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 5582</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6402</name>
      <address>
        <city>Medina</city>
        <state>Minnesota</state>
        <zip>55340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 1455</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 3828</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8046</name>
      <address>
        <city>Granville</city>
        <state>Ohio</state>
        <zip>43023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6313</name>
      <address>
        <city>Powell</city>
        <state>Ohio</state>
        <zip>43065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 9082</name>
      <address>
        <city>Chambersburg</city>
        <state>Pennsylvania</state>
        <zip>17201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8028</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 5163</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <results_first_submitted>September 13, 2021</results_first_submitted>
  <results_first_submitted_qc>September 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2021</results_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry eye</keyword>
  <keyword>MGD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03956225/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03956225/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 15 investigative sites located in the United States.</recruitment_details>
      <pre_assignment_details>Of the 299 enrolled subjects, 63 were excluded prior to randomization as screen failures. This reporting group includes all randomized subjects/eyes (236/472).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>iLux</title>
          <description>Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes were treated.</description>
        </group>
        <group group_id="P2">
          <title>LipiFlow</title>
          <description>Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes were treated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): All randomized subjects exposed to any study treatment evaluated in this study</population>
      <group_list>
        <group group_id="B1">
          <title>iLux</title>
          <description>Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes were treated.</description>
        </group>
        <group group_id="B2">
          <title>LipiFlow</title>
          <description>Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes were treated.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="236"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="13.4"/>
                    <measurement group_id="B2" value="56.2" spread="14.1"/>
                    <measurement group_id="B3" value="57.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Squares Mean Change From Baseline in Meibomian Gland Score (MGS) at Month 12</title>
        <description>Meibomian glands on the eyelids were assessed by the examiner using a Meibomian Gland Evaluator and a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated for each eye and scored from 0 to 3, with a resultant overall score (MGS) of 0 to 45 for each eye. Scoring was follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A higher change from baseline score indicates an improvement in meibomian gland function.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>Full Analysis Set with data at visit</population>
        <group_list>
          <group group_id="O1">
            <title>iLux</title>
            <description>Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes were treated.</description>
          </group>
          <group group_id="O2">
            <title>LipiFlow</title>
            <description>Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes were treated.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Change From Baseline in Meibomian Gland Score (MGS) at Month 12</title>
          <description>Meibomian glands on the eyelids were assessed by the examiner using a Meibomian Gland Evaluator and a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated for each eye and scored from 0 to 3, with a resultant overall score (MGS) of 0 to 45 for each eye. Scoring was follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A higher change from baseline score indicates an improvement in meibomian gland function.</description>
          <population>Full Analysis Set with data at visit</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="1.97"/>
                    <measurement group_id="O2" value="17.8" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority in change from baseline in MGS was declared if the lower confidence limit (LCL) was greater than -5.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <estimate_desc>Standard Error of the Least Squares Mean is presented. Least squares mean difference (iLux minus LipiFlow). Lower Confidence Limit is presented.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE's) were collected from time of consent to study exit, up to 12 months.</time_frame>
      <desc>AE's were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator. &quot;At Risk&quot; population for ocular AEs is reported in units of eyes; all other populations are reported in units of participants. This analysis population includes all subjects/eyes exposed to any study treatment evaluated in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pretreatment</title>
          <description>Events reported in this group occurred prior to exposure to the study treatment</description>
        </group>
        <group group_id="E2">
          <title>iLux Ocular</title>
          <description>Events reported in this group occurred in eyes treated with the iLux device</description>
        </group>
        <group group_id="E3">
          <title>iLux Nonocular</title>
          <description>Events reported in this group occurred in subjects treated with the iLux device</description>
        </group>
        <group group_id="E4">
          <title>LipiFlow Ocular</title>
          <description>Events reported in this group occurred in eyes treated with the LipiFlow device</description>
        </group>
        <group group_id="E5">
          <title>LipiFlow Nonocular</title>
          <description>Events reported in this group occurred in subjects treated with the LipiFlow device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. CDMA Project Lead, Ocular Health</name_or_title>
      <organization>Alcon Research, LLC</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

